[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582432":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":123,"collaborators":21,"id":125,"slug":126,"hasResults":127,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":21,"eligibilityCriteria":131,"healthyVolunteers":127,"sex":132,"minAge":133,"maxAge":21,"enrollmentInfo":134,"targetDuration":21,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":43,"whyStopped":21,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Metastatic non-small cell lung cancer (NSCLC)","EXPERIMENTAL","Participants will have a diagnosis of metastatic non-small cell lung cancer (NSCLC)",[13,14],"Drug: Zirconium Zr 89 crefmirlimab berdoxam","Diagnostic Test: PET\u002FCT Scan",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Zirconium Zr 89 crefmirlimab berdoxam","Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DIAGNOSTIC_TEST","PET\u002FCT Scan","Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET\u002FCT 24 hours later (+\u002F- 3 hours).",[9],[28],{"name":29,"affiliation":5,"role":30},"Adam Schoenfeld, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","646-608-4042","schoenfa@mskcc.org",{"name":37,"role":33,"phone":38,"phoneExt":21,"email":39},"Alexander Shoushtari, MD","646-888-4161","shoushta@mskcc.org",[41,57,68,79,91,102,112],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Memorial Sloan Kettering at Basking Ridge (Consent Only)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-74.54932,40.70621,{"lat":53,"lon":52},[56],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":58,"status":43,"city":59,"state":45,"zip":60,"country":47,"countryCode":48,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Memorial Sloan Kettering Monmouth (Consent Only)","Middletown","07748",{"type":50,"coordinates":62},[63,64],-74.11709,40.39428,{"lat":64,"lon":63},[67],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":69,"status":43,"city":70,"state":45,"zip":71,"country":47,"countryCode":48,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Memorial Sloan Kettering Bergen (Consent Only)","Montvale","07645",{"type":50,"coordinates":73},[74,75],-74.02292,41.04676,{"lat":75,"lon":74},[78],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":80,"status":43,"city":81,"state":82,"zip":83,"country":47,"countryCode":48,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)","Commack","New York","11725",{"type":50,"coordinates":85},[86,87],-73.29289,40.84288,{"lat":87,"lon":86},[90],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":92,"status":43,"city":93,"state":82,"zip":94,"country":47,"countryCode":48,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Memorial Sloan Kettering Westchester (Consent only)","Harrison","10604",{"type":50,"coordinates":96},[97,98],-73.71263,40.96899,{"lat":98,"lon":97},[101],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":103,"status":43,"city":82,"state":82,"zip":104,"country":47,"countryCode":48,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Memorial Sloan Kettering Cancer Center (All protocol activities)","10065",{"type":50,"coordinates":106},[107,108],-74.00597,40.71427,{"lat":108,"lon":107},[111],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"facility":113,"status":43,"city":114,"state":82,"zip":115,"country":47,"countryCode":48,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)","Uniondale","11553",{"type":50,"coordinates":117},[118,119],-73.59291,40.70038,{"lat":119,"lon":118},[122],{"name":29,"role":33,"phone":34,"phoneExt":21,"email":21},{"type":124,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100582432","phase-1-a-study-of-cd8-t-cell-imaging-during-treatment-in-people-with-non-small-cell-lung-cancer-100582432",false,"NCT06863233","A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer","Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging","Inclusion Criteria:\n\n* Patient must be 18 years of age or older at the time of signing the informed consent.\n* Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer\n* Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.\n* Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.\n* Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)","ALL","18 Years",{"count":135,"type":136},5,"ESTIMATED","INTERVENTIONAL",[139],"PHASE1","The purpose of this study to learn whether PET\u002FCT (positron emission tomography\u002Fcomputed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells",[142,143,144],"Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer",[142,143,144,5,146],"24-369","2025-08-11",{"date":149,"type":150},"2025-08-12","ACTUAL",{"date":152,"type":150},"2025-03-03",{"date":154,"type":136},"2028-03-03",{"name":5,"class":6},7]